MedPath

Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T

Not Applicable
Completed
Conditions
Ataxia Telangiectasia
Interventions
Procedure: Lumbar puncture
Registration Number
NCT02285348
Lead Sponsor
Johann Wolfgang Goethe University Hospital
Brief Summary

Ataxia telangiectasia (A-T) is a rare devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability, and cancer susceptibility. The underlying mechanism and process of neurodegeneration leading to loss of cerebellar neurons and neurological function is largely unknown. Laboratory diagnostic approaches to neurodegeneration in A-T are hampered by sampling issues. It is dangerous, impractical, and not ethically to directly sample brain tissue by surgical biopsy. In contrast cerebrospinal fluid (CSF), a fluid that is in direct contact with brain tissue, is relatively easy to sample in a safe procedure (lumbar puncture). The aim of the proposal is to investigate oxidative stress, low grade inflammation and tissue break down in the brain of A-T patients by analyzing CSF. In addition the alterations in protein expression related to A-T will be quantified by liquid chromatography/mass spectrometry (LC/MS)-based proteomic analysis of CSF from healthy individuals and A-T patients to determine candidate proteins (new biomarkers) which relative expression levels could be used as surrogate marker of disease progression.

Detailed Description

Ataxia telangiectasia (A-T) is a devastating human recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, chromosomal instability, and cancer susceptibility. For clinicians and scientists the underlying mechanism and process of neurodegeneration leading to loss of cerebellar neurons and neurological function is largely unknown. In addition no surrogate marker of neurological degeneration and disease progression exist.

Three major factors may be responsible for progression of neurodegeneration:

1. A-T patients exhibit elevated levels of reactive oxygen species (ROS) and reduced anti-oxidative capacity. It has been proposed that ROS is responsible for destruction of the purkinje cells in the cerebellum.

2. Ongoing low grade inflammation due to immunodeficiency. Elevated serum interleukin-8 (IL-8) levels in patients with A-T are postulated that systemic inflammation may contribute to the disease phenotype. How inflammation and neurodegeneration interact is, however, a matter of ongoing debate.

3. Low levels of growth hormones (GH). Extracerebellar MRI - lesions in A-T go along with deficiency of the GH axis, high Ataxia scores and advanced age.

The aim of the proposal is to investigate oxidative stress, low grade inflammation, tissue breakdown and biomarkers in cerebrospinal fluid (CSF), a fluid that is in direct contact with central nervous system (CNS), of A-T patients.

* To analyse functional gene expression of oxidative stress and low grade inflammation by means of reverse transcriptase-polymerase chain reaction (RT-PCR) and cytometric bead array.

* To characterize the alterations in protein expression related to A-T, a LC/MS-based quantitative proteomic analysis of CSF from control and A-T patients

* To compare alterations in protein expression levels in CSF with MRI findings in different age groups of classical A-T.

* To determine candidate proteins whose relative expression levels could be used as surrogate marker of disease progression?

* To established an analysis system on a basis of multiplex ELISA-technique to evaluate potential candidates/surrogate markers for disease progression in a larger cohort of patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
18
Inclusion Criteria
  • Aim group: clinically and/or genetically diagnosed Ataxia telangiectasia; Control group: neurologic non-inflammatory disease with an indication for diagnostic or therapeutic lumbar puncture
  • age between 2 and 40 years
  • written informed consent
Exclusion Criteria
  • fever or clinical signs of an infection
  • leucocyte count >12´000/µl and C reactive protein (CrP) >2mg/dl
  • chronic diseases with need of immunomodulatory therapies (bronchial asthma, rheumatoid arthritis)
  • medication with statins
  • other diseases with influence in the immunosystem (i.e. diabetes mellitus, malignoma, renal failure requiring dialysis)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ataxia TelangiectasiaLumbar puncture20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
Healthy ControlLumbar puncture20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
Primary Outcome Measures
NameTimeMethod
Concentration of IL-8 and oxidative stress in cerebrospinal fluid24 months

• To analyse functional gene expression of oxidative stress and low grade inflammation by means of RT-PCR and cytometric bead array.

Secondary Outcome Measures
NameTimeMethod
Alterations in protein expression levels in CSF with MRI findings in different age groups of classical A-T. Candidate proteins whose relative expression levels could be used as surrogate marker of disease progression.24 months
Alterations in protein expression related to A-T24 months

• Alterations in protein expression related to A-T, a LC/MS-based quantitative proteomic analysis of CSF from controls and A-T patients

Number of Participants with Adverse Events24 months

Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Alterations in protein expression levels in CSF compared with MRI findings in different age groups of classical A-T.24 months

Trial Locations

Locations (1)

Johann Wolfgang Goethe University Hospitals

🇩🇪

Frankfurt, Hessen, Germany

© Copyright 2025. All Rights Reserved by MedPath